Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy

Marie Donaldson, Joshua L. Owen, Young Kwang Chae, Jennifer N. Choi*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly used to treat several malignancies, with the most common adverse event being cutaneous toxicity. We report the case of a 68-years-old man with stage IV non-small cell lung cancer treated with nivolumab who developed a pruritic, lichenoid eruption refractory to treatment with topical or systemic steroids, who was started on narrow band ultraviolet B therapy which resolved the reaction.

Original languageEnglish (US)
Article number405
JournalFrontiers in Oncology
Volume8
DOIs
StatePublished - Sep 25 2018

Keywords

  • dermatitis
  • immunotherapy
  • lichenoid
  • nivolumab
  • non-small cell lung cancer
  • PD-1 inhibitor
  • phototherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy'. Together they form a unique fingerprint.

  • Cite this